Intra-Cellular Therapies

Intra-Cellular Therapies, Inc. (ITI) is a biopharmaceutical company that is developing novel drugs for the treatment of diseases and disorders of the Central Nervous System (CNS). Building on the science generated from the Nobel Prize winning laboratory of Dr. Paul Greengard at The Rockefeller University, the Company develops compounds that have the potential to treat a wide range of diseases associated with the central nervous system. To aid in the development process, the Company incorporates its CNSProfile™, a state-of-the-art platform that allows ITI to choose compounds with the strongest potential to succeed in these difficult to treat diseases

Type
Public
HQ
New York, US
Employees
37 (est)
Intra-Cellular Therapies is headquartered in New York, US

Intra-Cellular Therapies Locations

New York, US

Intra-Cellular Therapies Metrics

Intra-Cellular Therapies Summary

Market capitalization

$588 M

Closing share price

$13.9
Intra-Cellular Therapies's current market capitalization is $588 M.

Intra-Cellular Therapies Financials

Intra-Cellular Therapies's revenue is $91.4 K in FY, 2015 which is 84.17% decrease from the previous period.
FY, 2013FY, 2014FY, 2015

Revenue

$2.74 M$577 K$91.4 K

Operating income

$-26.3 M$-31 M$-106 M

Operating expense total

$29 M$31.6 M$106 M

Net Income

$-26.9 M$-30.7 M$-105 M

Operating cash flow

$19.5 M$26.2 M$-14.2 M

    Intra-Cellular Therapies Market Value History

    We estimate that Intra-Cellular Therapies's current employees are approximately 22% female and 78% male.

    Intra-Cellular Therapies News

    Intra-Cellular Therapies Company Life